Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women

被引：54
|
作者：
Roustit, Matthieu [2 ]
Jlaiel, Malik
Leclercq, Pascale [3 ]
Stanke-Labesque, Francoise [1 ,2 ,4 ]
机构：
[1] CHU Grenoble, Hop A Michallon, Pharmacol Lab, F-38043 Grenoble 9, France
[2] INSERM, ERI 17, Lab HP2, Grenoble, France
[3] CHU Grenoble, Clin Infectiol CISIH, F-38043 Grenoble 9, France
[4] Univ Grenoble 1, Fac Med, IFR1, Grenoble, France
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 66卷 / 02期
关键词：
antiretrovirals; HIV mother-to-child transmission; pharmacokinetics; pregnancy; protease inhibitors; therapeutic drug monitoring;
D O I：
10.1111/j.1365-2125.2008.03220.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Highly active antiretroviral therapy is recommended for HIV-infected pregnant women to prevent mother-to-child transmission. The specific physiological background induced by pregnancy leads to significant changes in maternal pharmacokinetics, suggesting potential variability in plasma concentrations of antiretrovirals during gestation. Therapeutic drug monitoring (TDM) of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) is recommended in certain situations, including pregnancy, but its systematic use in HIV-infected pregnant women remains controversial. This review provides an update of the pharmacokinetic data available for PIs and NNRTIs in pregnant women and highlights the clinical interest of systematic TDM of certain antiretroviral drugs during pregnancy, including nevirapine, nelfinavir, saquinavir, indinavir and lopinavir.
引用
收藏
页码：179 / 195
页数：17
相关论文
共 50 条
  • [21] Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
    Asselin, Barbara
    Rizzari, Carmelo
    LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2273 - 2280
  • [22] Pharmacokinetics and drug-drug interactions of antiretrovirals: An update
    Dickinson, Laura
    Khoo, Saye
    Back, David
    ANTIVIRAL RESEARCH, 2010, 85 (01) : 176 - 189
  • [23] Therapeutic drug monitoring in HIV-infected pregnant women with a focus on protease inhibitors
    Waqas, Sarmad
    Lambert, John S.
    FUTURE VIROLOGY, 2015, 10 (07) : 915 - 922
  • [24] Therapeutic drug monitoring (TDM) of antiretrovirals (ARVs) in a South London HIV clinic
    Grant, A.
    Boon, G.
    Castelino, S.
    Fox, J.
    Kulasegaram, R.
    HIV MEDICINE, 2011, 12 : 79 - 79
  • [25] Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis
    Duran, Adriana S.
    Losso, Marcelo H.
    Salomon, Horacio
    Harris, D. Robert
    Pampuro, Sandra
    Soto-Ramirez, Luis E.
    Duarte, Geraldo
    de Souza, Ricardo S.
    Read, Jennifer S.
    AIDS, 2007, 21 (02) : 199 - 205
  • [26] Perioperative Cefepime Pharmacokinetics Using Therapeutic Drug Monitoring
    Paplaczyk, K.
    Rhodes, N.
    Weslander, E.
    Kaiho, T.
    Valadez, A.
    Kurihara, C.
    Galvin, S.
    Reed, G.
    Leonida, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S645 - S646
  • [27] CYCLOSPORINE - STRUCTURE, PHARMACOKINETICS, AND THERAPEUTIC DRUG-MONITORING
    VINE, W
    BOWERS, LD
    CRC CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1987, 25 (04): : 275 - 311
  • [28] Population pharmacokinetics of etoposide: Application to therapeutic drug monitoring
    Ciccolini, J
    Monjanel-Mouterde, S
    Bun, SS
    Blanc, C
    Duffaud, F
    Favre, R
    Durand, A
    THERAPEUTIC DRUG MONITORING, 2002, 24 (06) : 709 - 714
  • [29] CLINICAL PHARMACOKINETICS VERSUS THERAPEUTIC DRUG-MONITORING
    KRAMER, P
    JOHNSTON, P
    HOSPITAL FORMULARY, 1983, 18 (09): : 925 - 925
  • [30] Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
    Dolton, Michael J.
    Ray, John E.
    Chen, Sharon C. -A.
    Ng, Kingsley
    Pont, Lisa G.
    McLachlan, Andrew J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) : 4793 - 4799
12345